Cardiovascular devices market: size, growth and outlook 2026–2032

Cath-lab consumables are the most expensive consignment line in a hospital; Indian stents changed the price curve. Published estimates normalised to 2025 range from USD 83.4 bn to USD 83.4 bn; the Consulting Wallah central estimate is USD 83.0 bn, growing at about 7% a year to USD 136 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by rising CVD burden from diabetes, hypertension, obesity (CVD ~45% of NCD deaths in the Eastern Mediterranean region per WHO; Bahrain ~53.8% of deaths); ageing population: over-65s projected to double by 2050; shift to minimally invasive therapies - PCI, TAVR, mitral/tricuspid repair, leadless pacing, pulsed field ablation.

Context that matters for buyers and suppliers: Global cardiovascular devices market grew from USD 72.83 bn (2023) to USD 77.71 bn (2024). Interventional cardiology is the largest device segment; structural heart the fastest-growing. Saudi Arabia imports ~90% of medical devices; other GCC states ~85%. NCDs cause >70% of deaths in the region, with cardiovascular conditions ~45% (WHO).

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 83.4 bn–USD 83.4 bn; differences are mostly scope.

Included: the product category as named, across hospital, clinic, laboratory and home settings, including the consumables and service contracts that travel with it where sources report them together. Excluded: adjacent categories reported in their own markets. Global figures are quoted as published; regional figures are flagged by scope.

• Global cardiovascular devices market grew from USD 72.83 bn (2023) to USD 77.71 bn (2024) (MarketsandMarkets)
• Interventional cardiology is the largest device segment; structural heart the fastest-growing (MarketsandMarkets)
• Saudi Arabia imports ~90% of medical devices; other GCC states ~85% (PharmaKnowl)
• NCDs cause >70% of deaths in the region, with cardiovascular conditions ~45% (WHO) (PharmaKnowl)
• India stent ceiling from 1 Apr 2026: DES Rs 39,186.03; BMS Rs 10,762.15 (ex-GST), under Order S.O. 1587(E) (Medical Dialogues)
• Saudi CV devices forecast CAGR 9.12% (IMARC) vs UAE 5.87% (Mordor) - Saudi is the GCC growth engine (IMARC / Mordor via PharmaKnowl)
• GCC connected medical devices & wearables: USD 1.65 bn (2025) to ~USD 4.49 bn by 2032 (~18% CAGR), relevant to remote cardiac monitoring (MarkNtel via PharmaKnowl)

Where the GCC and India sit

• Saudi Arabia cardiovascular devices: USD 633.7 mn (2025) -> USD 1,390.1 mn (2034), 9.12% CAGR (2025) — IMARC Group
• Saudi Arabia cardiovascular devices (alt.): USD 527.33 mn (2025); USD 715.19 mn (2031) (2025) — Mordor Intelligence via PharmaKnowl
• UAE cardiovascular devices: USD 227.26 mn (2026) -> USD 302.31 mn (2031), 5.87% CAGR (2026) — Mordor Intelligence via PharmaKnowl
• GCC medical devices (context): USD 13 bn (2025) -> USD 28.2 bn (2035) (2025) — Market Research Future via PharmaKnowl
• GCC medtech import dependence: Saudi 90%; UAE/Qatar/Kuwait/Oman/Bahrain ~85% (n/a) — PharmaKnowl
• India interventional cardiology devices: USD 877.6 mn (2025) -> USD 1,862.6 mn (2034), 8.37% CAGR (2025) — IMARC Group

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: structural heart (TAVR, TMVR, tricuspid) is the fastest-growing segment globally; saudi CV devices growing ~9% CAGR - fastest in GCC - with cardiac centre build-out; leadless pacemakers and pulsed-field ablation expanding electrophysiology spend.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders: standardise the fleet or the product family across sites, tender on total cost of use with fill-rate and uptime KPIs, and dual-source the top lines — see our five-line scoring.
• Suppliers: GS1 data, in-country stock and service response are the differentiators after price; the Consulting Wallah Network carries GCC and Indian demand in this category.
• Investors: regional manufacturing or service capacity backed by procurement preference.

1. MarketsandMarkets / GlobeNewswire, Global Cardiovascular Devices Market to Reach USD 110.39 Billion by 2029 — globenewswire.com
2. IMARC Group, Saudi Arabia Cardiovascular Devices Market 2026-2034 — imarcgroup.com
3. PharmaKnowl, MedTech Industry Statistics in the Gulf Markets (GCC) — pharmaknowl.com
4. IMARC Group, India Interventional Cardiology Devices Market 2026-2034 — imarcgroup.com
5. Medical Dialogues, NPPA revises coronary stent prices, DES at Rs 39,186 and BMS at Rs 10,762 from April 2026 — medicaldialogues.in
6. MarketsandMarkets (via GlobeNewswire) (2025-11) — USD 77.71 bn (2024) to USD 110.39 bn (2029), CAGR 7.3% (2024-2029); scope: Global cardiovascular devices (diagnostic/monitoring + therapeutic/surgical); 2023 = USD 72.83 bn; interventional cardiology largest segment, structural heart fastest; North America largest region — source
7. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
8. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.